Laotian version of selumetinib generic drug makes stunning debut, bringing new hope to children with NF1!

Recently, a new product has been developed for patients 2 years old and above with 1 neurofibromatosis (NF1) and symptoms, A drug for children with inoperable plexiform neurofibromas (PN)——The Laotian generic version of Selumetinib (Selumetinib) is officially launched. NF1As a hereditary disease, one of its characteristic manifestations is the formation of plexiform neurofibromas. These tumors bring huge challenges to the health and life of children.

It is worth mentioning that the original drug of selumetinib has been launched in China and is included in the scope of medical insurance, providing domestic patients with more convenient treatment options. The price is about 20,000 yuan. For specific prices and medical insurance reimbursement ratios, please consult the local hospital pharmacy.

However, the price of foreign original drug selumetinib is still relatively high. But what is exciting is that Laos Lucius Pharmaceutical Company has successfully developed the world’s first generic drug of selumetinib. The price of this generic drug is much lower than that of the original drug, costing only more than 2,000 yuan. At the same time, its ingredients are highly consistent with the original drug, bringing more hope to children with NF1 and their families.

Plexiform neurofibromas (PN) are one of the common complications in children with NF1. The growth and development of these tumors may cause serious problems such as pain and functional impairment. For some children with inoperable PN, drug treatment has become an important means to control the disease.

Selumetinib, as a targeted drug, blocks the abnormal activation of the MAPK signaling pathway by inhibiting the activity of MEKkinase, thereby effectively inhibiting the growth and development of plexiform neurofibromas. Clinical trial results show that selumetinib has demonstrated significant efficacy in the treatment of children with NF1-related plexiform neurofibromas. It can not only slow down the growth of tumors, but also improve the symptoms of children.

However, it should be noted that selumetinib may cause some adverse reactions during use, such as skin rash, diarrhea, etc. Therefore, when using selumetinib to treat children with NF1-related plexiform neurofibromas, doctors need to closely monitor the children's condition changes and adverse reactions, and make adjustments and management according to the specific situation to ensure the safety and effectiveness of the treatment.